|
Length: 22 pages
April 26, 2005Time To Revitalize Lagging Pharma Portals Use Audience and Process Insights To Rethink Portal Investment by Laura Ramos This is a document excerptEXECUTIVE SUMMARY
Life sciences firms bought portals early, but their initial projects ran aground as departmental pilots failed to cross organizational boundaries or finance prerequisite infrastructure like user directories, security, and common taxonomy. Doubling down on next-generation investments, pharma firms must revise their portal strategy investments now and apply them to role-based processes that bridge functional boundaries. Using portals to support collaborative, ad hoc processes, large drug manufacturers will build Innovation Networks that offer big payoffs in new drug innovation and adaptive clinical trials.
|
Buy Risk Free
Download and print PDF immediately
Price: US $279.00 Our Money-Back Guarantee If you are not completely satisfied, return it for a full refund within three weeks of your online purchase. Already a Forrester Client? Log in to read this document. Archived Teleconference:
What Is The Value Of Social Media/Web 2.0 In Customer Marketing?
Original air date: Monday, May 05, 2008
|
|||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||